Andrew Benjamin Nixon, PhD

Associate Professor in Medicine
Member of the Duke Cancer Institute
Campus mail 133 Jones, Research Drive, Durham, NC 27710
Phone (919) 613-7883
Email address anixon@duke.edu

Andrew Nixon, PhD, MBA (Associate Professor of Medicine) is Director of the Phase I Biomarker Laboratory, which brings together clinical, translational and basic research to pursue the development of novel biomarkers defining mechanisms of sensitivity, resistance, and toxicity to given therapeutic drug classes, particularly anti-angiogenic agents. Additionally, the laboratory has been appointed as a Molecular Reference Laboratory for the Alliance oncology cooperative group, a national clinical trial research group sponsored by the National Cancer Institute. The laboratory has quality control procedures in place to address many of the issues involved in clinical trial research including determination of sample quantity, sample integrity, and sample heterogeneity. We have spent considerable time developing robust assays that utilize limited amounts of specimen while providing high quality data. Multiplex ELISA and gene expression arrays are used to analyze serially collected blood and paraffin samples archived from cancer patient clinical trials. This work has the potential to improve the efficacy and toxicity of current therapies and to guide the development of the next generation of anti-angiogenesis therapies for cancer and other diseases.

Education and Training

  • Ph.D., Wake Forest University, 1997

Publications

Sharma, Mayur, Cathy Schilero, David M. Peereboom, Brian P. Hobbs, Paul Elson, Glen H. J. Stevens, Keith McCrae, Andrew B. Nixon, and Manmeet S. Ahluwalia. “Phase II study of Dovitinib in recurrent glioblastoma..” J Neurooncol 144, no. 2 (September 2019): 359–68. https://doi.org/10.1007/s11060-019-03236-6.

PMID
31292802
Full Text

Innocenti, Federico, Chen Jiang, Alexander B. Sibley, Stefanie Denning, Amy S. Etheridge, Dorothy Watson, Donna Niedzwiecki, et al. “An initial genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients in CALGB 80303 (Alliance)..” Pharmacogenet Genomics 29, no. 6 (August 2019): 123–31. https://doi.org/10.1097/FPC.0000000000000375.

PMID
30889042
Full Text

Lin, Jiaxing, Alexander Sibley, Ivo Shterev, Andrew Nixon, Federico Innocenti, Cliburn Chan, and Kouros Owzar. “fastJT: An R package for robust and efficient feature selection for machine learning and genome-wide association studies..” Bmc Bioinformatics 20, no. 1 (June 13, 2019). https://doi.org/10.1186/s12859-019-2869-3.

PMID
31195980
Full Text

Kelly, Francine L., Kaitlyn E. Weinberg, Andrew E. Nagler, Andrew B. Nixon, Mark D. Star, Jamie L. Todd, David M. Brass, and Scott M. Palmer. “EGFR-Dependent IL8 Production by Airway Epithelial Cells After Exposure to the Food Flavoring Chemical 2,3-Butanedione..” Toxicol Sci 169, no. 2 (June 1, 2019): 534–42. https://doi.org/10.1093/toxsci/kfz066.

PMID
30851105
Full Text

Secord, Angeles Alvarez, Michael McCollum, Brittany A. Davidson, Gloria Broadwater, Robert Squatrito, Laura J. Havrilesky, Anne C. Gabel, et al. “Phase II trial of nintedanib in patients with bevacizumab-resistant recurrent epithelial ovarian, tubal, and peritoneal cancer..” Gynecol Oncol 153, no. 3 (June 2019): 555–61. https://doi.org/10.1016/j.ygyno.2019.03.246.

PMID
30929823
Full Text

Mettu, Niharika B., Donna Niedzwiecki, Christel Rushing, Andrew B. Nixon, Jingquan Jia, Sherri Haley, Wanda Honeycutt, Herbert Hurwitz, Johanna C. Bendell, and Hope Uronis. “A phase I study of gemcitabine + dasatinib (gd) or gemcitabine + dasatinib + cetuximab (GDC) in refractory solid tumors..” In Cancer Chemother Pharmacol, 83:1025–35, 2019. https://doi.org/10.1007/s00280-019-03805-6.

PMID
30895346
Full Text

Hsi, Eric D., Hongli Li, Andrew B. Nixon, Heiko Schöder, Nancy L. Bartlett, Michael LeBlanc, Sonali Smith, et al. “Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study..” Blood 133, no. 16 (April 18, 2019): 1762–65. https://doi.org/10.1182/blood-2018-08-870915.

PMID
30723079
Full Text

Choueiri, Toni K., M Dror Michaelson, Edwin M. Posadas, Guru P. Sonpavde, David F. McDermott, Andrew B. Nixon, Yingmiao Liu, et al. “An Open Label Phase Ib Dose Escalation Study of TRC105 (Anti-Endoglin Antibody) with Axitinib in Patients with Metastatic Renal Cell Carcinoma..” Oncologist 24, no. 2 (February 2019): 202–10. https://doi.org/10.1634/theoncologist.2018-0299.

PMID
30190302
Full Text

Corradetti, M. N., J. A. Torok, A. J. Hatch, E. P. Xanthopoulos, K. Lafata, C. Jacobs, C. Rushing, et al. “Dynamic Changes in Circulating Tumor DNA During Chemoradiation for Locally Advanced Lung Cancer.” Advances in Radiation Oncology, January 1, 2019. https://doi.org/10.1016/j.adro.2019.05.004.

Full Text

Innocenti, Federico, Chen Jiang, Alexander B. Sibley, Amy S. Etheridge, Ace J. Hatch, Stefanie Denning, Donna Niedzwiecki, et al. “Genetic variation determines VEGF-A plasma levels in cancer patients..” Sci Rep 8, no. 1 (November 5, 2018). https://doi.org/10.1038/s41598-018-34506-4.

PMID
30397360
Full Text

Pages